Of note, tumor cells that become addicted to pathway inhibitors proliferate with a very low level of ERK activation (only 2–3% of ERK was phosphorylated according to mass spectrometry) [31], indicating once more that anti-ERK therapies must inhibit the pathway with high efficiency to achieve an antiproliferative effect. The gene discussed is MAPK1; the disease is neoplasm.